Amsterdam, Netherlands – 27 Aug 2023: Immediate multivessel percutaneous coronary intervention (PCI) is non-inferior to staged multivessel PCI for reducing death and ischaemic events in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.1
Multivessel coronary artery disease is present in about half of patients with STEMI and is associated with increased risks of recurrent myocardial infarction and mortality.2-5 The COMPLETE trial demonstrated that among patients with STEMI and multivessel coronary artery disease, complete revascularisation was superior to culprit-lesion-only PCI for reducing ischaemic events and death.6 ESC guidelines state that routine revascularisation of non-infarct-related artery lesions should be considered in STEMI patients with multivessel coronary artery disease before hospital discharge.7 However, there is a lack of evidence on the optimal timing of multivessel PCI (immediate versus staged).7,8
The MULTISTARS AMI trial investigated whether immediate complete revascularisation at the time of primary PCI was non-inferior to staged (within 19 to 45 days) multivessel PCI among haemodynamically stable patients with STEMI and multivessel coronary artery disease.9
The trial included patients with acute STEMI (presenting within 24 hours of symptom onset) and multivessel coronary artery disease (defined as at least one coronary lesion with ≥70% diameter stenosis on coronary angiography based on visual estimation in a non-culprit coronary artery of ≥2.25 mm and ≤5.75 mm in diameter), who were haemodynamically stable after successful primary PCI of the infarct-related coronary artery.
Patients were randomly allocated in a 1:1 ratio to immediate or staged (within 19 to 45 days) PCI of the non-culprit lesions. The primary endpoint was a composite of all-cause death, non-fatal myocardial infarction, stroke, unplanned ischaemia-driven revascularisation, or hospitalisation for heart failure within one year after randomisation.
The trial enrolled 840 patients from 37 sites in Europe. The average age of participants was 65 years and 21.2% were women. At one year, the primary endpoint occurred in 35 patients (8.5%) in the immediate group and in 68 patients (16.3%) in the staged group (risk ratio 0.52; 95% confidence interval 0.38 to 0.72; p<0.001 for non-inferiority; p<0.001 for superiority). The median time interval from randomisation to staged procedures in the staged group was 37 (interquartile range 30-43) days.
Non-fatal myocardial infarction occurred in 8 patients (2.0%) in the immediate group and in 22 patients (5.3%) in the staged group (hazard ratio [HR] 0.36; 95% confidence interval [CI] 0.16 to 0.80), and unplanned ischaemia-driven revascularisation was performed in 17 patients (4.1%) in the immediate group and in 39 patients (9.3%) in the staged group (HR 0.42, 95%CI 0.24 to 0.74). Rates of all-cause death, stroke, and hospitalisation for heart failure did not differ between groups.
Principal investigator Dr. Barbara Stähli of the University Hospital Zurich, Switzerland, said: “MULTISTARS AMI addresses the clinically important question of the optimal timing for a complete revascularisation of patients with STEMI and multivessel coronary artery disease. The trial has implications for clinical practice, as it demonstrated that immediate PCI of non-culprit lesions is as effective and safe as a staged procedure. Results were generally consistent across prespecified key subgroups, particularly among women and men, young and older patients, and patients with or without diabetes.”
ENDS
Our mission: To reduce the burden of cardiovascular disease.